Adverse events to monoclonal antibodies used for cancer therapy focus on hypersensitivity responses

OncoImmunology

Volumn 2, Issue 10, 2013, Pages

  Baldo, Brian A ^a,b  

^a ROYAL NORTH SHORE HOSPITAL   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Adverse effects; Cancer; Cardiac events; Hemolytic anemia; Hypersensitivity; Infusion reactions; Lung disease; MAbs; Monoclonal antibodies; Neutropenia; Serum sickness; Thrombocytopenia; Vasculitis

Indexed keywords

BEVACIZUMAB; BEXXA; BRENTUXIMAB VEDOTIN; CATUMAXOMAB; CETUXIMAB; IBRITUMOMAB TIUXETAN; MONOCLONAL ANTIBODY; PANITUMUMAB; RITUXIMAB; TOSITUMOMAB I 131; TRASTUZUMAB; UNCLASSIFIED DRUG;

ACNE; ADVERSE DRUG REACTION; ALLERGIC PNEUMONITIS; ALLERGIC REACTION; ALOPECIA; ANAPHYLAXIS; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; AUTOIMMUNE DISEASE; BRONCHOSPASM; BULLOUS DERMATITIS; BULLOUS SKIN DISEASE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CARDIOTOXICITY; COLORECTAL CANCER; CYTOKINE RELEASE SYNDROME; CYTOPENIA; DIAGNOSTIC ACCURACY; DIARRHEA; DISEASE CLASSIFICATION; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; ERYTHEMA; ERYTHRODERMA; GASTROINTESTINAL SYMPTOM; HEAD AND NECK CANCER; HEADACHE; HEMOLYTIC ANEMIA; HODGKIN DISEASE; HUMAN; HYPERHIDROSIS; HYPERSENSITIVITY; IMMEDIATE TYPE HYPERSENSITIVITY; INFUSION RELATED REACTION; INTERSTITIAL PNEUMONIA; LARGE CELL LYMPHOMA; LICHENOID ERUPTION; LUNG DISEASE; LUNG HEMORRHAGE; MALIGNANT ASCITES; NAIL DISEASE; NONHODGKIN LYMPHOMA; NONHUMAN; PARANEOPLASTIC PEMPHIGUS; PARONYCHIA; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PRURITUS; RASH; SKIN ALLERGY; SKIN MANIFESTATION; SWEAT GLAND DISEASE; SYSTEMIC DISEASE; THROMBOCYTOPENIA; TUMOR BLEEDING; TUMOR LYSIS SYNDROME; VASCULITIS; XERODERMA;

EID: 84890281406     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.26333     Document Type: Article

References (170)

1. World Health Organization. International drug monitoring: The role of national centres. WHO Tec Rep Ser 1972; 498:1-25
2. Edwards IR, Aronson JK. Adverse drug reactions: Definitions, diagnosis, and management. Lancet 2000; 356:1255-9; PMID:11072960; http://dx.doi.org/10.1016/S0140-6736(00)02799-9
3. What is a serious event? Available at http:/www.fda. gov/safety/medwatch/howtoreport/ucm053087.htm (accessed February 18, 2013).
4. Meyer UA. Pharmacogenetics and adverse drug reactions. Lancet 2000; 356:1667-71; PMID:11089838; http://dx.doi.org/10.1016/S0140-6736(00)03167-6
5. Coombs RRA, Gell PGH. Classification of allergic reactions responsible for clinical hypersensitivity and disease. In: Gell PGH, Coombs RRA, Lachmann PJ, eds. Clinical Aspects of Immunology. Oxford: Blackwells, 1975: 761-81.
6. Brockow K, Romano A, Aberer W, Bircher AJ, Barbaud A, Bonadonna P, Faria E, Kanny G, Lerch M, Pichler WJ, et al.; European Network of Drug Allergy and the EAACI interest group on drug hypersensitivity. Skin testing in patients with hypersensitivity reactions to iodinated contrast media - a European multicenter study. Allergy 2009; 64:234-41; PMID:19178403; http://dx.doi.org/10.1111/j.1398-9995.2008.01832.x
7. Vane JR. The mode of action of aspirin and similar compounds. J Allergy Clin Immunol 1976; 58:691-712; PMID:791988; http://dx.doi.org/10.1016/0091-6749(76)90181-0
8. Baldo BA, Pham NH. Drug Allergy. Clinical Aspects, Diagnosis, Mechanisms, Structure-Activity Relationships. New York: Springer, 2013.
9. Weiss RB, Baker JR Jr. Hypersensitivity reactions from antineoplastic agents. Cancer Metastasis Rev 1987; 6:413-32; PMID:3319275; http://dx.doi. org/10.1007/BF00144273
10. Ardavanis A, Tryfonopoulos D, Yiotis I, Gerasimidis G, Baziotis N, Rigatos G. Non-allergic nature of docetaxel-induced acute hypersensitivity reactions. Anticancer Drugs 2004; 15:581-5; PMID:15205600; http://dx.doi.org/10.1097/01.cad.0000131685.06390.b7
11. Went P, Vasei M, Bubendorf L, Terracciano L, Tornillo L, Riede U, Kononen J, Simon R, Sauter G, Baeuerle PA. Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers. Br J Cancer 2006; 94:128-35; PMID:16404366; http://dx.doi.org/10.1038/sj.bjc.6602924
12. Linke R, Klein A, Seimetz D. Catumaxomab: Clinical development and future directions. MAbs 2010; 2:129-36; PMID:20190561; http://dx.doi.org/10.4161/mabs.2.2.11221
13. Cragg MS, Walshe CA, Ivanov AO, Glennie MJ. The biology of CD20 and its potential as a target for mAb therapy. Curr Dir Autoimmun 2005; 8:140-74; PMID:15564720; http://dx.doi. org/10.1159/000082102
14. Shim H. One target, different effects: A comparison of distinct therapeutic antibodies against the same targets. Exp Mol Med 2011; 43:539-49; PMID:21811090; http://dx.doi.org/10.3858/emm.2011.43.10.063
15. Jacene HA, Filice R, Kasecamp W, Wahl RL. Comparison of 90Y-ibritumomab tiuxetan and 131I-tositumomab in clinical practice. J Nucl Med 2007; 48:1767-76; PMID:17942813; http://dx.doi.org/10.2967/jnumed.107.043489
16. Wahl RL. Tositumomab and (131)I therapy in non- Hodgkin's lymphoma. J Nucl Med 2005; 46(Suppl 1):128S-40S; PMID:15653661
17. Jazirehi AR, Bonavida B. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention. Oncogene 2005; 24:2121- 43; PMID:15789036; http://dx.doi.org/10.1038/sj.onc.1208349
18. Hansel TT, Kropshofer H, Singer T, Mitchell JA, George AJT. The safety and side effects of monoclonal antibodies. Nat Rev Drug Discov 2010; 9:325-38; PMID:20305665; http://dx.doi.org/10.1038/nrd3003
19. Zhang B. Ofatumumab. MAbs 2009; 1:326-31; PMID:20068404; http://dx.doi.org/10.4161/ mabs.1.4.8895
20. Cardarelli PM, Quinn M, Buckman D, Fang Y, Colcher D, King DJ, Bebbington C, Yarranton G. Binding to CD20 by anti-B1 antibody or F(ab') (2) is sufficient for induction of apoptosis in B-cell lines. Cancer Immunol Immunother 2002; 51:15- 24; PMID:11845256; http://dx.doi.org/10.1007/s00262-001-0247-1
21. Li S, Schmitz KR, Jeffrey PD, Wiltzius JJ, Kussie P, Ferguson KM. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell 2005; 7:301-11; PMID:15837620; http://dx.doi.org/10.1016/j.ccr.2005.03.003
22. Freeman D, Sun J, Bass R, Jung K, Ogbagabriel S, Elliott G, et al. Panitumumab and cetuximab epitope mapping and in vitro activity. J Clin Oncol 2008; 26(suppl 20)
23. Hudis CA. Trastuzumab--mechanism of action and use in clinical practice. N Engl J Med 2007; 357:39-51; PMID:17611206; http://dx.doi.org/10.1056/NEJMra043186
24. Ghosh R, Narasanna A, Wang SE, Liu S, Chakrabarty A, Balko JM, González-Angulo AM, Mills GB, Penuel E, Winslow J, et al. Trastuzumab has preferential activity against breast cancers driven by HER2 homodimers. Cancer Res 2011; 71:1871-82; PMID:21324925; http://dx.doi.org/10.1158/0008-5472.CAN-10-1872
25. Niculescu-Duvaz I. Trastuzumab emtansine, an antibody-drug conjugate for the treatment of HER2+ metastatic breast cancer. Curr Opin Mol Ther 2010; 12:350-60; PMID:20521224
26. Persson M, Tolmachev V, Andersson K, Gedda L, Sandström M, Carlsson J. [(177)Lu]pertuzumab: experimental studies on targeting of HER-2 positive tumour cells. Eur J Nucl Med Mol Imaging 2005; 32:1457-62; PMID:16193312; http://dx.doi.org/10.1007/s00259-005-1902-0
27. Franklin MC, Carey KD, Vajdos FF, Leahy DJ, de Vos AM, Sliwkowski MX. Insights into ErbB signaling from the structure of the ErbB2- pertuzumab complex. Cancer Cell 2004; 5:317- 28; PMID:15093539; http://dx.doi.org/10.1016/S1535-6108(04)00083-2
28. Senter PD, Sievers EL. The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Nat Biotechnol 2012; 30:631- 7; PMID:22781692; http://dx.doi.org/10.1038/nbt.2289
29. Ellis LM. Mechanisms of action of bevacizumab as a component of therapy for metastatic colorectal cancer. Semin Oncol 2006; 33(Suppl 10):S1-7; PMID:17145519; http://dx.doi.org/10.1053/j.seminoncol.2006.08.002
30. Alinari L, Lapalombella R, Andritsos L, Baiocchi RA, Lin TS, Byrd JC. Alemtuzumab (Campath-1H) in the treatment of chronic lymphocytic leukemia. Oncogene 2007; 26:3644-53; PMID:17530018; http://dx.doi.org/10.1038/sj.onc.1210380
31. Hu Y, Turner MJ, Shields J, Gale MS, Hutto E, Roberts BL, Siders WM, Kaplan JM. Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model. Immunology 2009; 128:260-70; PMID:19740383; http://dx.doi.org/10.1111/j.1365-2567.2009.03115.x
32. Hanley DA, Adachi JD, Bell A, Brown V. Denosumab: mechanism of action and clinical outcomes. Int J Clin Pract 2012; 66:1139-46; PMID:22967310; http://dx.doi.org/10.1111/ijcp.12022
33. Tarhini AA, Iqbal F. CTLA-4 blockade: therapeutic potential in cancer treatments. Onco Targets Ther 2010; 3:15-25; PMID:20616954; http://dx.doi.org/10.2147/OTT.S4833
34. European Medicines Agency evaluation of medicines for human use. Assessment report for Removab. Proc. no. EMEA/H/C/000972, 2009. Available at http:// www.ema.europa.eu/docs /en_GB/document_ l ibra r y/EPAR_-Publ ic _a s se s sment_repor t / human/000972/WC500051808.pdf (accessed at July 1, 2013).
35. Therapeutic Goods Administration. Australian public assessment report for catumaxomab, October 2012. Available at http://www.tga.gov.au/pdf/auspar/auspar-catumaxomab-121004.pdf (accessed July 1, 2013).
36. Zevalin®. FDA: Full prescribing information. Adverse reactions. Available at http://www.accessdata.fda. gov/drugsatfda_docs/label/2009/125019s0156.pdf (accessed July 1, 2013).
37. Bexxar®. FDA: Full prescribing information. Adverse reactions. Available at http://www.accessdata.fda. gov/drugsatfda_docs/label/2012/125011s102lbl.pdf (accessed July 1, 2013).
38. Kaminski MS, Zelenetz AD, Press OW, Saleh M, Leonard J, Fehrenbacher L, Lister TA, Stagg RJ, Tidmarsh GF, Kroll S, et al. Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non- Hodgkin's lymphomas. J Clin Oncol 2001; 19:3918-3928; PMID:11579112
39. Adcetris®. FDA: Full prescribing information. Adverse reactions. Available at http://www.accessdata.fda. gov/drugsatfda_docs/label/2012/125388s0005lbl. pdf (accessed July 1, 2013).
40. Younes A, Bartlett NL, Leonard JP, Kennedy DA, Lynch CM, Sievers EL, Forero-Torres A. Brentuximab vedotin (SGN-35) for relapsed CD30- positive lymphomas. N Engl J Med 2010; 363:1812- 21; PMID:21047225; http://dx.doi.org/10.1056/ NEJMoa1002965
41. Erbitux®. FDA: Full prescribing information. Adverse reactions. Available at http://www.accessdata.fda. gov/drugsatfda_docs/label/2009/125084s168lbl.pdf (accessed July 1, 2013).
42. Thomas M. Cetuximab: adverse event profile and recommendations for toxicity management. Clin J Oncol Nurs 2005; 9:332-8; PMID:15973844; http://dx.doi.org/10.1188/05.CJON.332-338
43. Hoag JB, Azizi A, Doherty TJ, Lu J, Willis RE, Lund ME. Association of cetuximab with adverse pulmonary events in cancer patients: a comprehensive review. J Exp Clin Cancer Res 2009; 28:113; PMID:19682368; http://dx.doi.org/10.1186/1756-9966-28-113
44. Polito AJ. Pulmonary reactions to novel chemotherapeutic agents and biomolecules. In: Camus P, Rosenow III EC, eds. Drug-Induced and Iatrogenic Respiratory Disease. London: HodderArnold, 2010: 146-60.
45. Rituxan®. FDA: Full prescribing information. Adverse reactions. Available at http://www.ac c e s sdat a .fda.gov/drugsat fda _docs/label/2012/103705s5367s5388lbl.pdf (accessed July 1, 2013).
46. Ram R, Bonstein L, Gafter-Gvili A, Ben-Bassat I, Shpilberg O, Raanani P. Rituximab-associated acute thrombocytopenia: an under-diagnosed phenomenon. Am J Hematol 2009; 84:247-50; PMID:19260124; http://dx.doi.org/10.1002/ajh.21372
47. Wolach O, Bairey O, Lahav M. Late-onset neutropenia after rituximab treatment: case series and comprehensive review of the literature. Medicine (Baltimore) 2010; 89:308-18; PMID:20827108; http://dx.doi.org/10.1097/MD.0b013e3181f2caef
48. Le Guenno G, Ruivard M, Charra L, Philippe P. Rituximab-induced serum sickness in refractory immune thrombocytopenic purpura. Intern Med J 2011; 41:202-5; PMID:22747556; http://dx.doi.org/10.1111/j.1445-5994.2010.02384.x
49. Dereure O, Navarro R, Rossi JF, Guilhou JJ. Rituximab-induced vasculitis. Dermatology 2001; 203:83-4; PMID:11549810; http://dx.doi.org/10.1159/000051713
50. Lioté H, Lioté F, Séroussi B, Mayaud C, Cadranel J. Rituximab-induced lung disease: A systematic literature review. Eur Respir J 2010; 35:681-7; PMID:19608586; http://dx.doi.org/10.1183/09031936.00080209
51. Campath-1H®. FDA: Full prescribing information. Adverse reactions. Available at http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/103948s5070lbl.pdf (accessed July 1, 2013).
52. Lenihan DJ, Alencar AJ, Yang D, Kurzrock R, Keating MJ, Duvic M. Cardiac toxicity of alemtuzumab in patients with mycosis fungoides/Sézary syndrome. Blood 2004; 104:655-8; PMID:15073032; http://dx.doi.org/10.1182/blood-2003-07-2345
53. Sun WL, Walder A, Fiegl M. Haemolytic anaemia triggered by antitumoural "biological agents" and immunotherapies with monoclonal antibodies: short review of the literature. memo 2010; 3:19-22; http://dx.doi.org/10.1007/s12254-010-0174-y.
54. Avastin®. FDA: Full prescribing information. Adverse reactions. Available at http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/125085s0238lbl.pdf(accessed July 1, 2013).
55. Shord SS, Bressler LR, Tierney LA, Cuellar S, George A. Understanding and managing the possible adverse effects associated with bevacizumab. Am J Health Syst Pharm 2009; 66:999-1013; PMID:19451611; http://dx.doi.org/10.2146/ajhp080455
56. Sliesoraitis S, Tawfik B. Bevacizumab-induced bowel perforation. J Am Osteopath Assoc 2011; 111:437-41; PMID:21803880
57. Cortes J, Calvo V, Ramírez-Merino N, O'Shaughnessy J, Brufsky A, Robert N, Vidal M, Muñoz E, Perez J, Dawood S, et al. Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis. Ann Oncol 2012; 23:1130-7; PMID:21976387; http://dx.doi.org/10.1093/annonc/mdr432
58. Perjeta®. FDA: Full prescribing information. Adverse reactions. Available at http://www.accessdata.fda. gov/drugsatfda_docs/label/2012/125409lbl.pdf(accessed July 1, 2013).
59. Hubalek M, Brantner C, Marth C. Role of pertuzumab in the treatment of HER2-positive breast cancer. Breast Cancer: Targets and Therapy 2012; 4:65-73; http://dx.doi.org/10.2147/BCTT.S23560
60. Herceptin®. FDA: Full prescribing information. Adverse reactions. Available at http://www.accessdata. fda.gov/drugsatfda_docs/label/2010/103792s5256lbl.pdf(accessed July 1, 2013).
61. Parikh O, Neave F, Palmieri C. Severe thrombocytopenia induced by a single infusion of trastuzumab. Clin Breast Cancer 2008; 8:285- 6; PMID:18650161; http://dx.doi.org/10.3816/ CBC.2008.n.034
62. Kadcyla®. FDA: Full prescribing information. Adverse reactions. Available at http://www.accessdata.fda. gov/drugsatfda_docs /label /2013/125427lbl.pdf(accessed July 1, 2013).
63. Xgeva®. FDA: Full prescribing information. Adverse reactions. Available at http://www.accessdata.fda. gov/drugsatfda_docs/label/2013/125320s094lbl.pdf(accessed July 1, 2013).
64. Yervoy®. FDA: Full prescribing information. Adverse reactions. Available at http://www.accessdata.fda. gov/drugsatfda_docs/label/2011/125377s0000lbl.pdf (accessed July 1, 2013).
65. Weber J. Review: anti-CTLA-4 antibody ipilimumab: Case studies of clinical response and immunerelated adverse events. Oncologist 2007; 12:864- 72; PMID:17673617; http://dx.doi.org/10.1634/ theoncologist.12-7-864
66. Tarhini A. Immune-mediated adverse events associated with ipilimumab CTLA-4 blockade therapy: The underlying mechanisms and clinical management. Scientifica 2013; Forthcoming; http://dx.doi.org/10.1155/2013/857519
67. Arzerra®. FDA: Full prescribing information. Adverse reactions. Available at http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/125326lbl.pdf(accessed July 1, 2013).
68. Lemery SJ, Zhang J, Rothmann MD, Yang J, Earp J, Zhao H, McDougal A, Pilaro A, Chiang R, Gootenberg JE, et al. U.S. Food and Drug Administration approval: ofatumumab for the treatment of patients with chronic lymphocytic leukemia refractory to fludarabine and alemtuzumab. Clin Cancer Res 2010; 16:4331-8; PMID:20601446; http://dx.doi.org/10.1158/1078-0432.CCR-10-0570
69. Vectibix®. FDA: Full prescribing information. Adverse reactions. Available at http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/125147s080lbl.pdf(accessed July 1, 2013).
70. Stephens S, Emtage S, Vetterlein O, Chaplin L, Bebbington C, Nesbitt A, Sopwith M, Athwal D, Novak C, Bodmer M. Comprehensive pharmacokinetics of a humanized antibody and analysis of residual anti-idiotypic responses. Immunology 1995; 85:668-74; PMID:7558164
71. Aster RH, Bougie DW. Drug-induced immune thrombocytopenia. N Engl J Med 2007; 357:580- 7; PMID:17687133; http://dx.doi.org/10.1056/NEJMra066469
72. Kenney B, Stack G. Drug-induced thrombocytopenia. Arch Pathol Lab Med 2009; 133:309-14; PMID:19195976
73. Salama A, Schütz B, Kiefel V, Breithaupt H, Mueller- Eckhardt C. Immune-mediated agranulocytosis related to drugs and their metabolites: mode of sensitization and heterogeneity of antibodies. Br J Haematol 1989; 72:127-32; PMID:2788011; http://dx.doi.org/10.1111/j.1365-2141.1989.tb07672.x
74. Berliner N, Horwitz M, Loughran TP Jr. Congenital and acquired neutropenia. Hematology Am Soc Hematol Educ Program 2004:63-79; PMID:15561677; http://dx.doi.org/10.1182/ asheducation-2004.1.63
75. Garratty G. Drug-induced immune hemolytic anemia. Hematology Am Soc Hemat Educ Program 2009; 73-9.
76. Agache IO, Rogozea L. Management of hypersensitivity pneumonitis. Clin Translational Allergy 2013;Forthcoming; 3:5; http://dx.doi.org/10.1186/2045-7022-3-5
77. Castell JV, Castell M. Allergic hepatitis induced by drugs. Curr Opin Allergy Clin Immunol 2006; 6:258-65; PMID:16825865
78. Adams DH, Ju C, Ramaiah SK, Uetrecht J, Jaeschke H. Mechanisms of immune-mediated liver injury. Toxicol Sci 2010; 115:307-21; PMID:20071422; http://dx.doi.org/10.1093/toxsci/kfq009
79. Apisamthanarax N, Duvic M. Dermatologic complications of cancer chemotherapy. In: Bast RC Jr, Kufe DW, Pollock RE, et al. eds. Holland-Frei Cancer Medicine, 5th edn. Hamilton, Ontario: BC Decker, 2000: 2271-8.
80. Lynch TJ Jr., Kim ES, Eaby B, Garey J, West DP, Lacouture ME. Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management. Oncologist 2007; 12:610-21; PMID:17522250; http://dx.doi.org/10.1634/theoncologist.12-5-610
81. Balagula Y, Lacouture ME, Cotliar JA. Dermatologic toxicities of targeted anticancer therapies. J Support Oncol 2010; 8:149-61; PMID:20822032
82. Common terminology criteria for adverse events v3.0, DTCD, NCI, NIH, DHHS. Publish date: August 9, 2006 (http:/ctep.cancer.gov)
83. Lenz HJ. Management and preparedness for infusion and hypersensitivity reactions. Oncologist 2007; 12:601-9; PMID:17522249; http://dx.doi.org/10.1634/theoncologist.12-5-601
84. O'Neil BH. Overview of hypersensitivity to cancer therapies. Community Oncol 2010; 7:11-6; http://dx.doi.org/10.1016/S1548-5315(11)70383-7
85. Joerger M. Prevention and handling of acute allergic and infusion reactions in oncology. Ann Oncol 2012; 23(Suppl 10):x313-9; PMID:22987983; http://dx.doi.org/10.1093/annonc/mds314
86. Howard SC, Jones DP, Pui CH. The tumor lysis syndrome. N Engl J Med 2011; 364:1844-54; PMID:21561350; http://dx.doi.org/10.1056/NEJMra0904569
87. Bhatt V, Saleem A. Review: Drug-induced neutropenia--pathophysiology, clinical features, and management. Ann Clin Lab Sci 2004; 34:131-7; PMID:15228223
88. Lee A, ed. Adverse Drug Reactions, 2nd edn. London: Pharmaceutical Press, 2006.
89. Uetrecht J, ed. Adverse Drug Reactions. Handbook of Experimental Pharmacology 196. Heidelberg: Springer-Verlag, 2010.
90. Kimby E. Tolerability and safety of rituximab (MabThera). Cancer Treat Rev 2005; 31:456-73; PMID:16054760; http://dx.doi.org/10.1016/j. ctrv.2005.05.007
91. Kang SP, Saif MW. Infusion-related and hypersensitivity reactions of monoclonal antibodies used to treat colorectal cancer--identification, prevention, and management. J Support Oncol 2007; 5:451-7; PMID:18019853
92. Chung CH, Mirakhur B, Chan E, Le QT, Berlin J, Morse M, Murphy BA, Satinover SM, Hosen J, Mauro D, et al. Cetuximab-induced anaphylaxis and IgE specific for galactose-a-1,3-galactose. N Engl J Med 2008; 358:1109-17; PMID:18337601; http://dx.doi.org/10.1056/NEJMoa074943
93. Jankowitz R, Joyce J, Jacobs SA. Anaphylaxis after administration of ibritumomab tiuxetan for follicular non-hodgkin lymphoma. Clin Nucl Med 2008; 33:94-6; PMID:18209526; http://dx.doi.org/10.1097/RLU.0b013e31815ef825
94. Vultaggio A, Matucci A, Nencini F, Pratesi S, Petroni G, Cammelli D, et al. Drug-specific Th2 cells and IgE antibodies in a patient with anaphylaxis to rituximab. In Arch Allergy Immunol 2012; 159:321-6.
95. Sallman DA, Macklin E, Ali S, Michaelson J, Barnes JA, Abramson JS, et al. Rituximab hypersensitivity reactions (HSR): Predictors of recurrent and severe reactions based on severity of reaction, NHL histologic subtype, and burden of disease. J Clin Oncol 2012; 30(Suppl)
96. Dillman RO. Infusion reactions associated with the therapeutic use of monoclonal antibodies in the treatment of malignancy. Cancer Metastasis Rev 1999; 18:465-71; PMID:10855789; http://dx.doi.org/10.1023/A:1006341717398
97. Chung CH. Managing premedications and the risk for reactions to infusional monoclonal antibody therapy. Oncologist 2008; 13:725-32; PMID:18586928; http://dx.doi.org/10.1634/theoncologist.2008-0012
98. Winkler U, Jensen M, Manzke O, Schulz H, Diehl V, Engert A. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDECC2B8). Blood 1999; 94:2217-24; PMID:10498591
99. Tonini G, Santini D, Vincenzi B, Borzomati D, Dicuonzo G, La Cesa A, Onori N, Coppola R. Oxaliplatin may induce cytokine-release syndrome in colorectal cancer patients. J Biol Regul Homeost Agents 2002; 16:105-9; PMID:12144121
100. Hayslip J, Fenning R. Safe administration of iodine-131 tositumomab after repeated infusionrelated reactions to rituximab. Oncologist 2007; 12:338-40; PMID:17405899; http://dx.doi.org/10.1634/theoncologist.12-3-338
101. Diehl LF, Ketchum LH. Autoimmune disease and chronic lymphocytic leukemia: autoimmune hemolytic anemia, pure red cell aplasia, and autoimmune thrombocytopenia. Semin Oncol 1998; 25:80-97; PMID:9482530
102. McLaughlin P, Grillo-López AJ, Link BK, Levy R, Czuczman MS, Williams ME, Heyman MR, Bence- Bruckler I, White CA, Cabanillas F, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16:2825-33; PMID:9704735
103. Cattaneo C, Spedini P, Casari S, Re A, Tucci A, Borlenghi E, Ungari M, Ruggeri G, Rossi G. Delayed-onset peripheral blood cytopenia after rituximab: frequency and risk factor assessment in a consecutive series of 77 treatments. Leuk Lymphoma 2006; 47:1013-7; PMID:16840190; http://dx.doi.org/10.1080/10428190500473113
104. Otrock ZK, Mahfouz RA, Oghlakian GO, Salem ZM, Bazarbachi A. Rituximab-induced acute thrombocytopenia: a report of two cases. Haematologica 2005; 90(Suppl):ECR23; PMID:16266914
105. Cathomas R, Goldhirsch A, Von Moos R. Correspondence. Drug induced thrombocytopenia. N Engl J Med 2007; 357:1870-1; PMID:17985437
106. Jara Sánchez C, Olier Gárate C, García-Donas Jiménez J, Peñalver Párraga J. Drug-induced thrombocytopenia induced by trastuzumab: a special challenge in a curable disease. Ann Oncol 2009; 20:1607-8; PMID:19633054; http://dx.doi.org/10.1093/annonc/mdp374
107. Haider I, Cahill M. Fatal thrombocytopaenia temporally related to the administration of alemtuzumab (MabCampath) for refractory CLL despite early discontinuation of therapy. Hematology 2004; 9:409-11; PMID:15763982; http://dx.doi.org/10.1080/10245330400001942
108. Coles AJ, Compston DA, Selmaj KW, Lake SL, Moran S, Margolin DH, Norris K, Tandon PK; CAMMS223 Trial Investigators. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med 2008; 359:1786-801; PMID:18946064; http://dx.doi.org/10.1056/NEJMoa0802670
109. Gibbs SD, Westerman DA, McCormack C, Seymour JF, Miles Prince H. Severe and prolonged myeloid haematopoietic toxicity with myelodysplastic features following alemtuzumab therapy in patients with peripheral T-cell lymphoproliferative disorders. Br J Haematol 2005; 130:87-91; PMID:15982349; http://dx.doi.org/10.1111/j.1365-2141.2005.05570.x
110. Scappaticci FA, Skillings JR, Holden SN, Gerber HP, Miller K, Kabbinavar F, Bergsland E, Ngai J, Holmgren E, Wang J, et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 2007; 99:1232-9; PMID:17686822; http://dx.doi.org/10.1093/jnci/djm086
111. Nalluri SR, Chu D, Keresztes R, Zhu X, Wu S. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA 2008; 300:2277-85; PMID:19017914; http://dx.doi.org/10.1001/jama.2008.656
112. Dunleavy K, Tay K, Wilson WH. Rituximabassociated neutropenia. Semin Hematol 2010; 47:180-6; PMID:20350665; http://dx.doi.org/10.1053/j.seminhematol.2010.01.009
113. Voog E, Morschhauser F, Solal-Céligny P. Neutropenia in patients treated with rituximab. N Engl J Med 2003; 348:2691-4, discussion 2691-4; PMID:12826650; http://dx.doi.org/10.1056/ NEJM200306263482620
114. Papadaki T, Stamatopoulos K, Stavroyianni N, Paterakis G, Phisphis M, Stefanoudaki-Sofianatou K. Evidence for T-large granular lymphocyte-mediated neutropenia in Rituximab-treated lymphoma patients: report of two cases. Leuk Res 2002; 26:597-600; PMID:12007508; http://dx.doi.org/10.1016/S0145-2126(01)00183-7
115. Liu JH, Wei S, Lamy T, Epling-Burnette PK, Starkebaum G, Djeu JY, Loughran TP. Chronic neutropenia mediated by fas ligand. Blood 2000; 95:3219-22; PMID:10807792
116. Papadaki T, Stamatopoulos K, Anagnostopoulos A, Fassas A. Rituximab-associated immune myelopathy. Blood 2003; 102:1557-8; PMID:12900357; http://dx.doi.org/10.1182/blood-2003-05-1532
117. Terrier B, Ittah M, Tourneur L, Louache F, Soumelis V, Lavie F, Casadevall N, Candon S, Hummel A, Mariette X, et al. Late-onset neutropenia following rituximab results from a hematopoietic lineage competition due to an excessive BAFF-induced B-cell recovery. Haematologica 2007; 92:e20-3; PMID:17405749; http://dx.doi.org/10.3324/ haematol.11031
118. Jourdan E, Topart D, Richard B, Jourdan J, Sotto A. Severe autoimmune hemolytic anemia following rituximab therapy in a patient with a lymphoproliferative disorder. Leuk Lymphoma 2003; 44:889-90; PMID:12802933; http://dx.doi. org/10.1080/1042819021000055110
119. Ramamoorthy SK, Marangolo M, Durrant E, Akima S, Gottlieb DJ. Unusual reaction to Rituximab with intra-vascular hemolysis, rhabdomyolysis, renal failure and bone marrow necrosis. Leuk Lymphoma 2006; 47:747-50; PMID:16690535
120. Ruch J, McMahon B, Ramsey G, Kwaan HC. Catastrophic multiple organ ischemia due to an anti-Pr cold agglutinin developing in a patient with mixed cryoglobulinemia after treatment with rituximab. Am J Hematol 2009; 84:120-2; PMID:19097173; http:// dx.doi.org/10.1002/ajh.21330
121. Elimelakh M, Dayton V, Park KS, Gruessner AC, Sutherland D, Howe RB, Reding MT, Eastlund T, van Burik JA, Singleton TP, et al. Red cell aplasia and autoimmune hemolytic anemia following immunosuppression with alemtuzumab, mycophenolate, and daclizumab in pancreas transplant recipients. Haematologica 2007; 92:1029-36; PMID:17640860; http://dx.doi.org/10.3324/ haematol.10733
122. Kako S, Kanda Y, Oshima K, Nishimoto N, Sato H, Watanabe T, Hosoya N, Motokura T, Miyakoshi S, Taniguchi S, et al. Late onset of autoimmune hemolytic anemia and pure red cell aplasia after allogeneic hematopoietic stem cell transplantation using in vivo alemtuzumab. Am J Hematol 2008; 83:247-9; PMID:17918251; http://dx.doi.org/10.1002/ajh.21086
123. Fiegl M, Falkner A, Hopfinger G, Brugger S, Zabernigg A, Bauer F, et al. Routine clinical use of alemtuzumab in patients with heavily pretreated B-cell chronic lymphocytic leukemia: a nationwide retrospective study in Austria. Cancer 2006; 107:2408-16; PMID:17054106; http://dx.doi.org/10.1002/cncr.22263
124. Wierda WG, Kipps TJ, Keating MJ, Brown JR, Gribben JG, Browning M, Rassenti LZ, Greaves AW, Neuberg D, O'Brien SM; CLL Research Consortium. Self-administered, subcutaneous alemtuzumab to treat residual disease in patients with chronic lymphocytic leukemia. Cancer 2011; 117:116-24; PMID:20806349; http://dx.doi.org/10.1002/cncr.25379
125. Frangié C, Lefaucheur C, Medioni J, Jacquot C, Hill GS, Nochy D. Renal thrombotic microangiopathy caused by anti-VEGF-antibody treatment for metastatic renal-cell carcinoma. Lancet Oncol 2007; 8:177-8; PMID:17267332; http://dx.doi.org/10.1016/S1470-2045(07)70037-2
126. Eremina V, Jefferson JA, Kowalewska J, Hochster H, Haas M, Weisstuch J, Richardson C, Kopp JB, Kabir MG, Backx PH, et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 2008; 358:1129-36; PMID:18337603; http://dx.doi.org/10.1056/NEJMoa0707330
127. Anandacoomarasamy A, Kannangara S, Barnsley L. Cutaneous vasculitis associated with infliximab in the treatment of rheumatoid arthritis. Intern Med J 2005; 35:638-40; PMID:16207269; http://dx.doi.org/10.1111/j.1445-5994.2005.00899.x
128. Kandula P, Kouides PA. Rituximab-induced leukocytoclastic vasculitis: a case report. Arch Dermatol 2006; 142:243-53; PMID:16490860; http://dx.doi.org/10.1001/archderm.142.2.246
129. Kim MJ, Kim HO, Kim HY, Park YM. Rituximabinduced vasculitis: A case report and review of the medical published work. J Dermatol 2009; 36:284-7; PMID:19382999; http://dx.doi.org/10.1111/j.1346-8138.2009.00639.x
130. D'Arcy CA, Mannik M. Serum sickness secondary to treatment with the murine-human chimeric antibody IDEC-C2B8 (rituximab). Arthritis Rheum 2001; 44:1717-8; PMID:11465726; http://dx.doi.org/10.1002/1529-0131(200107)44:71717::AIDART299 3.0.CO;2-C
131. Hellerstedt B, Ahmed A. Delayed-type hypersensitivity reaction or serum sickness after rituximab treatment. Ann Oncol 2003; 14:1792; PMID:14630688; http://dx.doi.org/10.1093/annonc/mdg488
132. Finger E, Scheinberg M. Development of serum sickness-like symptoms after rituximab infusion in two patients with severe hypergammaglobulinemia. J Clin Rheumatol 2007; 13:94-5; PMID:17414540; http://dx.doi.org/10.1097/01.rhu.0000262585.18582.1e
133. Fong L, Small EJ. Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment. J Clin Oncol 2008; 26:5275-83; PMID:18838703; http://dx.doi.org/10.1200/JCO.2008.17.8954
134. Maker AV, Attia P, Rosenberg SA. Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade. J Immunol 2005; 175:7746-54; PMID:16301685
135. Weber J. Review: anti-CTLA-4 antibody ipilimumab: Case studies of clinical response and immunerelated adverse events. Oncologist 2007; 12:864-72; PMID:17673617; http://dx.doi.org/10.1634/ theoncologist.12-7-864
136. Agache IO, Rogozea L. Management of hypersensitivity pneumonitis. Clin Translational Allergy 2013; 3:5; http://dx.doi.org/10.1186/2045-7022-3-5
137. Ergin AB, Fong N, Daw HA. Rituximab-induced bronchiolitis obliterans organizing pneumonia. Case Rep Med 2012; 2012:680431; PMID:22778751; http://dx.doi.org/10.1155/2012/680431
138. Burton C, Kaczmarski R, Jan-Mohamed R. Interstitial pneumonitis related to rituximab therapy. N Engl J Med 2003; 348:2690-1, discussion 2690-1; PMID:12826649; http://dx.doi.org/10.1056/NEJM200306263482619
139. Wagner SA, Mehta AC, Laber DA. Rituximabinduced interstitial lung disease. Am J Hematol 2007; 82:916-9; PMID:17597477; http://dx.doi.org/10.1002/ajh.20910
140. Kishi J, Nanki T, Watanabe K, Takamura A, Miyasaka N. A case of rituximab-induced interstitial pneumonitis observed in systemic lupus erythematosus. Rheumatology (Oxford) 2009; 48:447-8; PMID:19202159; http://dx.doi.org/10.1093/rheumatology/kep015
141. Hadjinicolaou AV, Nisar MK, Parfrey H, Chilvers ER, Ostör AJK. Non-infectious pulmonary toxicity of rituximab: a systematic review. Rheumatology (Oxford) 2012; 51:653-62; PMID:22157468; http://dx.doi.org/10.1093/rheumatology/ker290
142. Chaumais MC, Garnier A, Chalard F, Peuchmaur M, Dauger S, Jacqz-Agrain E, Deschênes G. Fatal pulmonary fibrosis after rituximab administration. Pediatr Nephrol 2009; 24:1753-5; PMID:19396468; http://dx.doi.org/10.1007/s00467-009-1195-9
143. Kamei K, Ito S, Iijima K. Severe respiratory adverse events associated with rituximab infusion. Pediatr Nephrol 2010; 25:1193; PMID:20024586; http://dx.doi.org/10.1007/s00467-009-1408-2
144. Child N, O'Carroll M, Berkahn L. Rituximabinduced interstitial lung disease in a patient with immune thrombocytopenia purpura. Intern Med J 2012; 42:e12-4; PMID:22432995; http://dx.doi.org/10.1111/j.1445-5994.2011.02701.x
145. Arulkumaran N, Suleman R, Cecconi M, Kiely P, Chua F. Rituximab associated pneumonitis in antineutrophil cytoplasmic antibody-associated vasculitis. J Clin Rheumatol 2012; 18:39-41; PMID:22157278; http://dx.doi.org/10.1097/RHU.0b013e31823ee5bf
146. Montero AJ, McCarthy JJ, Chen G, Rice L. Acute respiratory distress syndrome after rituximab infusion. Int J Hematol 2005; 82:324-6; PMID:16298824; http://dx.doi.org/10.1532/IJH97.NA0506
147. Benyunes MC, Multani PS, Saunders A. Interstitial pneumonitis related to rituximab therapy. N Engl J Med 2003; 348:2691; PMID:12826650
148. Alho HS, Maasilta PK, Harjula AL, Hämmäinen P, Salminen J, Salminen US. Tumor necrosis factoralpha in a porcine bronchial model of obliterative bronchiolitis. Transplantation 2003; 76:516-23; PMID:12923437; http://dx.doi.org/10.1097/01. TP.0000074700.30536.76
149. Alexandrescu DT, Dutcher JP, O'Boyle K, Albulak M, Oiseth S, Wiernik PH. Fatal intra-alveolar hemorrhage after rituximab in a patient with non-Hodgkin lymphoma. Leuk Lymphoma 2004; 45:2321-5; PMID:15512824; http://dx.doi.org/10.1 080/10428190410001697359
150. Gonçalo M, Bruynzeel DP. Mechanisms in cutaneous drug hypersensitivity reactions. In: Zhai H, Wilhelm KP, Maibach HI, eds. Marzulli and Maibach's Dermatotoxicology, 7th edn. Boca Raton Florida: CRC Press, 2008: 259-68.
151. Lowndes S, Darby A, Mead G, Lister A. Stevens-Johnson syndrome after treatment with rituximab. Ann Oncol 2002; 13:1948-50; PMID:12453865; http://dx.doi.org/10.1093/annonc/mdf350
152. Scheinfeld N. A review of rituximab in cutaneous medicine. Dermatol Online J 2006; 12:3; PMID:16638371
153. Segaert S, Van Cutsem E. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol 2005; 16:1425-33; PMID:16012181; http://dx.doi.org/10.1093/ annonc/mdi279
154. Melosky B, Burkes R, Rayson D, Alcindor T, Shear N, Lacouture M. Management of skin rash during EGFR-targeted monoclonal antibody treatment for gastrointestinal malignancies: Canadian recommendations. Curr Oncol 2009; 16:16-26; PMID:19229368; http://dx.doi.org/10.3747/co.v16i1.361
155. Mitchell EP, Pérez-Soler R, Van Cutsem E, Lacouture ME. Clinical presentation and pathophysiology of EGFRI dermatologic toxicities. Oncology (Williston Park) 2007; 21(Suppl 5):4-9; PMID:18154212
156. Klein PM, Dybdal N. Trastuzumab and cardiac dysfunction: Update on preclinical studies. Semin Oncol 2003; 30(Suppl 16):49-53; PMID:14613026; http://dx.doi.org/10.1053/j.seminoncol.2003.08.007
157. Crone SA, Zhao YY, Fan L, Gu Y, Minamisawa S, Liu Y, Peterson KL, Chen J, Kahn R, Condorelli G, et al. ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat Med 2002; 8:459-65; PMID:11984589; http://dx.doi.org/10.1038/nm0502-459
158. Grazette LP, Boecker W, Matsui T, Semigran M, Force TL, Hajjar RJ, Rosenzweig A. Inhibition of ErbB2 causes mitochondrial dysfunction in cardiomyocytes: implications for herceptin-induced cardiomyopathy. J Am Coll Cardiol 2004; 44:2231-8; PMID:15582322; http://dx.doi.org/10.1016/j.jacc.2004.08.066
159. Howard SC, Jones DP, Pui CH. The tumor lysis syndrome. N Engl J Med 2011; 364:1844-54; PMID:21561350; http://dx.doi.org/10.1056/NEJMra0904569
160. Brooks B. Progressive multifocal leukoencephalopathy. In: Gilman S ed. Neurobiology of Disease. London: Elsevier Academic Press, 2007: 185-96.
161. Carson KR, Evens AM, Richey EA, Habermann TM, Focosi D, Seymour JF, Laubach J, Bawn SD, Gordon LI, Winter JN, et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: A report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 2009; 113:4834-40; PMID:19264918; http://dx.doi.org/10.1182/blood-2008-10-186999
162. Johansson SGO, Bieber T, Dahl R, Friedmann PS, Lanier BQ, Lockey RF, Motala C, Ortega Martell JA, Platts-Mills TA, Ring J, et al. Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. J Allergy Clin Immunol 2004; 113:832-6; PMID:15131563; http://dx.doi.org/10.1016/j.jaci.2003.12.591
163. Reese JA, Li X, Hauben M, Aster RH, Bougie DW, Curtis BR, George JN, Vesely SK. Identifying drugs that cause acute thrombocytopenia: An analysis using 3 distinct methods. Blood 2010; 116:2127-33; PMID:20530792; http://dx.doi.org/10.1182/ blood-2010-03-276691
164. Arnold DM, Santoso S, Greinacher A; Platelet Immunology Scientific Subcommittee of the ISTH. Recommendations for the implementation of platelet autoantibody testing in clinical trials of immune thrombocytopenia. J Thromb Haemost 2012; 10:695-7; PMID:22332994; http://dx.doi.org/10.1111/j.1538-7836.2012.04664.x
165. Stroncek DF. Drug-induced immune neutropenia. Transfus Med Rev 1993; 7:268-74; PMID:8241615; http://dx.doi.org/10.1016/S0887-7963(93)70146-7
166. Radic M, Martinovic Kaliterna D, Radic J. Druginduced vasculitis: A clinical and pathological review. Neth J Med 2012; 70:12-7; PMID:22271809
167. Matsuno O. Drug-induced interstitial lung disease: mechanisms and best diagnostic approaches. Respir Res 2012; 13:39; PMID:22651223; http://dx.doi.org/10.1186/1465-9921-13-39
168. Ellis SJ, Cleverley JR, Müller NL. Drug-induced lung disease: high-resolution CT findings. AJR Am J Roentgenol 2000; 175:1019-24; PMID:11000156; http://dx.doi.org/10.2214/ajr.175.4.1751019
169. Epler GR. Bronchiolitis obliterans organizing pneumonia, 25 years: A variety of causes, but what are the treatment options?. Expert Rev Respir Med 2011; 5:353-61; PMID:21702658; http://dx.doi.org/10.1586/ers.11.19
170. Baldo BA, Pham NH. Adverse reactions to targeted and non-targeted chemotherapeutic drugs with emphasis on hypersensitivity responses and the invasive metastatic switch. Cancer Metastasis Rev 2013; Forthcoming; PMID:24043487; http://dx.doi.org/10.1007/s10555-013-9447-3